Citigroup’s Krystal Biotech KRYS Stock Holding History

Citigroup’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200	Closed	-$35.3K	–	6273
2025 Q3	$35.3K	Sell	200 -17,800	-99%	-$2.66M	﹤0.01%	4601
2025 Q2	$2.47M	Hold	18,000	–	–	﹤0.01%	2451
2025 Q1	$3.25M	Sell	18,000 -2,000	-10%	-$336K	﹤0.01%	2292
2024 Q4	$3.13M	Buy	+20,000	New	+$3.55M	﹤0.01%	2428
2023 Q4	–	Sell	-12,400	Closed	-$1.44M	–	5788
2023 Q3	$1.44M	Buy	+12,400	New	+$1.51M	﹤0.01%	2236
2023 Q2	–	Sell	-8,300	Closed	-$664K	–	5653
2023 Q1	$664K	Buy	+8,300	New	+$652K	﹤0.01%	2890

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citigroup's KRYS Position: Q2 2026 in Review

Citigroup increased its Krystal Biotech (KRYS) stake by 80% in Q2 2026, buying an estimated $7.42M and bringing the position to 56,016 shares worth $20.8M. The position accounts for 0.01% of the portfolio, ranked #1153.

Citigroup first reported a position in KRYS in Q4 2018 and has held it in 31 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Citigroup held 56,016 shares of Krystal Biotech worth $20.8M as of Q2 2026.
Citigroup bought 24,844 Krystal Biotech shares in Q2 2026, an estimated $7.42M.
Krystal Biotech made up 0.01% of Citigroup's portfolio in Q2 2026, its #1153 holding.
Citigroup first reported a position in Krystal Biotech in Q4 2018 and has held it in 31 quarters since.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.